

**Cork University Hospital & Cork University Maternity Hospital
Blood Component/Product
Prescription & Transfusion Record**
Use for Paediatric or Obstetric Patients Only.
(Use Form No. 15A for adult and non-obstetric patients.)

First Name: _____
Surname: _____
MRN: _____ DOB: _____
Ward: _____

**Transfusion Associated Circulatory Overload (TACO) Risk Assessment Tool
for Red Cell Transfusions in Non-Bleeding Patients**

Does this patient have any of the following risk factors?

- Does the patient have a diagnosis of 'heart failure', congestive cardiac failure, severe aortic stenosis or moderate to severe left ventricular dysfunction?
- Is the patient on a regular diuretic?
- Does the patient have severe anaemia?
- Is the patient known to have pulmonary oedema?
- Does the patient have respiratory symptoms of undiagnosed cause?
- Is the fluid balance clinically significantly positive?
- Is the patient on concomitant fluids (or has been in the past 24 hours)?
- Is there any peripheral oedema?
- Does the patient have hypocalcaemia?
- Does the patient have significant renal impairment?



Due to differences in adult and neonatal physiology, babies may have a different risk for TACO. Calculate the dose by weight and observe the notes above. *(This Risk Assessment tool was created by the Serious Hazards of Transfusion (SHOT) group in the UK.)*

(Seek advice from senior medical staff, if necessary.)

If the patient has any risk factors:

- 1** Review the need for the transfusion: do the benefits outweigh the risks?
- 2** Can the transfusion be safely deferred until the issue can be investigated, treated or resolved?
- 3** Consider body weight dosing (especially for adults <50 Kg & children <40 Kg).
Transfuse one unit (red cells) and review symptoms of anaemia.
Measure the fluid balance.
Consider a prophylactic diuretic.
Transfuse at a slower rate, over a maximum of 4 hours.
Monitor the vital signs closely.

Single Unit Prescription & Transfusion

- Stable normovolaemic non-bleeding adult inpatients who require transfusion should initially be prescribed a single unit of RCC, as this is often sufficient to relieve acute symptoms of anaemia and/or sufficiently raise their haemoglobin so that further transfusion may be unnecessary or can be replaced by an alternative treatment (e.g. oral or IV iron).
- **1 RCC** typically increases the haemoglobin of a **70 kg** person by **1 g/dL**, so the increase will be greater for people with a lower body weight.
- After transfusion, re-assess the patient clinically (+/- check their Hb) to determine if further transfusion is required.
- In stable non-bleeding patients, the FBC can be checked ≥ 10 minutes after transfusion completion.
- Prescribe each unit on a separate line in the prescription panel below.
- To cancel a prescription, draw a line through the relevant prescription, then sign and date the cancellation.
- Remember: **Don't Transfuse Two, if One will do!**



Prescribed on:	Date	Time	Blood Component or Product Prescribed:	Special Requirements: * (Refer to Page 9, then circle as appropriate)	Risk of TACO?	Number of units/Volume (See pg. 2 & 3)	Prophylactic Drug Therapy Prescribed? (Please circle)	Rate / Duration of Transfusion (See pg. 2 & 3)	Has the patient received the patient information leaflet? (Circle as appropriate)	Doctor's signature	IMC number	Bleep no. / Contact details	Transfused? (Tick when prescription fulfilled)
				CMV Neg	Yes		Yes		Yes				
				CMV Neg	Yes		Yes		Yes				
				CMV Neg	Yes		Yes		Yes				
				CMV Neg	Yes		Yes		Yes				
				CMV Neg	Yes		Yes		Yes				
				CMV Neg	Yes		Yes		Yes				
				CMV Neg	Yes		Yes		Yes				
				CMV Neg	Yes		Yes		Yes				
				CMV Neg	Yes		Yes		Yes				
				CMV Neg	Yes		Yes		Yes				
				CMV Neg	Yes		Yes		Yes				
				CMV Neg	Yes		Yes		Yes				
				CMV Neg	Yes		Yes		Yes				
				CMV Neg	Yes		Yes		Yes				
				CMV Neg	Yes		Yes		Yes				
				CMV Neg	Yes		Yes		Yes				

* For special requirements other than irradiated or CMV negative (e.g. HLA matched; washed components etc.), please seek consultant haematologist advice.

For guidance on prescribing blood components/products, including special requirements, refer to PPG-CUH-CUH-30 on QPULSE.

Essential Information for Prescribing and Administering Blood Components/Products to Paediatric or Obstetric Patients

	Red Cell Concentrate (RCC)	Platelets	Solvent Detergent (SD) Plasma	Fibrinogen (RiaSTAP® 1g)
Storage	Refrigerated at 4 ± 2°C	Incubated & agitated at 22 ± 2°C NEVER refrigerate platelets.	Frozen until required, then refrigerated at 4 ± 2°C	Refrigerated at 2 - 8°C
Volume per unit	Full pack: 226 – 350 mL 5 split paediatric pack: 54 - 71 mL in each split.	Full pack: 220 – 340 mL Paediatric platelet aliquot: ≥ 50 mL - depending on the volume requested.	200 mL (nominal volume)	50 mL when reconstituted with sterile water.
Typical transfusion volume/dose in non-bleeding patients	Adults: 4 mL/Kg Single unit transfusions should be given to non-bleeding adult patients where possible. Consider weight based prescribing if the adult is <50 Kg . Neonatal 'Top ups': 10 – 20 mL/Kg, typically 15 mL/Kg or use transfusion formula below. (BSH 2016) Infants & Children: For children < 40 Kg , calculate transfusion volume in mL using the formula: (Desired Hb [g/dL] – actual Hb [g/dL]) x wt [Kg] x 4 The volume transfused should NOT exceed 2 g/dL above the transfusion threshold. Normal maximum transfusion volume is 1 unit. (BSH 2016) 4 mL/Kg increases Hb by approximately 1g/dL. (BSH 2017) 1 unit increases Hb of a 70 Kg adult by approximately 1 g/dL. Adults: 2 – 5 mL/Kg/hr Routine administration for adult patients NOT at risk of TACO is 90 – 120 minutes/unit (BSH 2017). If at risk of TACO, transfuse over a longer period, up to a maximum of 4 hours. Neonates, infants & children >1 year old: 2 – 5 mL/Kg/hr (usual maximum rate = 150 mL/hr) (BSH 2016) All Patients: Rapid transfusion may be appropriate in the management of major haemorrhage (BSH 2017).	Adults: Single unit transfusion where possible and then re-check the platelet count ≥ 10 minutes after transfusion to determine if another platelet transfusion is needed. Neonates, Infants & Children < 15 Kg: 10 – 20 mL/Kg (BSH 2016) Children ≥ 15 Kg: Single ABO compatible apheresis donation (approximately 300 mL). <u>Maximum volume</u> = 1 pack (BSH 2016) 1 unit increases platelet count of a 70 Kg adult by approx. 20 – 40 x 10 ⁹ /L Adults: Typically administered over 30 – 60 minutes per adult therapeutic dose (ATD) (i.e. 1 unit). (BSH 2017) Neonates, infants & Children: 10 – 20 mL/Kg/hr (BSH 2016)	Adults: Dosage depends on patient's weight & clinical situation. 12-15 mL/Kg is the generally accepted starting dose. (LG- Octaplas SPC 2019) Neonates, Infants & Children: 12 – 15 mL/kg Adults, Neonates, Infants & Children: Dosage for plasma exchange: Seek advice from consultant haematologist. Depends on clinical indication, pre- and post-transfusion coagulation tests and clinical response. After transfusion, repeat coagulation tests to determine if further doses are required. Adults: 30 – 60 minutes per 200 mL <u>QI</u> 10 - 20 mL/Kg/hr Neonates, Infants & Children: 10 - 20 mL/Kg/hr (BSH 2016) All Patients: Transfuse patients at risk of TACO at a slower rate. Rapid transfusion may be appropriate during major haemorrhage, but the rate must NOT exceed 1 mL/Kg/min , as can cause citrate toxicity. (LG- Octaplas SPC 2019)	Obstetric patients: In the event of haemorrhage, administer fibrinogen promptly & maintain levels >2.0 g/L . Non-obstetric adult patients: In the event of haemorrhage, maintain levels >1.5 g/L . Neonates, Infants & Children: In the event of haemorrhage, maintain levels >1.5 g/L . Depends on clinical situation – refer to product insert and to PPG-CUH-CUH-209. After administration, re-check patient's fibrinogen level. Refer to product insert and to PPG-CUH-CUH-209 on QPULSE. Administer slowly at a rate which the patient finds comfortable and which does NOT exceed 5 mL/min.
Expected increment/unit	4 mL/Kg increases Hb by approximately 1g/dL. (BSH 2017) 1 unit increases Hb of a 70 Kg adult by approximately 1 g/dL.	1 unit increases platelet count of a 70 Kg adult by approx. 20 – 40 x 10 ⁹ /L	Depends on clinical indication, pre- and post-transfusion coagulation tests and clinical response. After transfusion, repeat coagulation tests to determine if further doses are required. Adults: 30 – 60 minutes per 200 mL <u>QI</u> 10 - 20 mL/Kg/hr Neonates, Infants & Children: 10 - 20 mL/Kg/hr (BSH 2016) All Patients: Transfuse patients at risk of TACO at a slower rate. Rapid transfusion may be appropriate during major haemorrhage, but the rate must NOT exceed 1 mL/Kg/min , as can cause citrate toxicity. (LG- Octaplas SPC 2019)	Depends on clinical situation – refer to product insert and to PPG-CUH-CUH-209. After administration, re-check patient's fibrinogen level. Refer to product insert and to PPG-CUH-CUH-209 on QPULSE. Administer slowly at a rate which the patient finds comfortable and which does NOT exceed 5 mL/min.
Transfusion Rate/Duration (non-emergencies)	Adults: 2 – 5 mL/Kg/hr Routine administration for adult patients NOT at risk of TACO is 90 – 120 minutes/unit (BSH 2017). If at risk of TACO, transfuse over a longer period, up to a maximum of 4 hours. Neonates, infants & children >1 year old: 2 – 5 mL/Kg/hr (usual maximum rate = 150 mL/hr) (BSH 2016) All Patients: Rapid transfusion may be appropriate in the management of major haemorrhage (BSH 2017).	Adults: Typically administered over 30 – 60 minutes per adult therapeutic dose (ATD) (i.e. 1 unit). (BSH 2017) Neonates, infants & Children: 10 – 20 mL/Kg/hr (BSH 2016)	Adults: 30 – 60 minutes per 200 mL <u>QI</u> 10 - 20 mL/Kg/hr Neonates, Infants & Children: 10 - 20 mL/Kg/hr (BSH 2016) All Patients: Transfuse patients at risk of TACO at a slower rate. Rapid transfusion may be appropriate during major haemorrhage, but the rate must NOT exceed 1 mL/Kg/min , as can cause citrate toxicity. (LG- Octaplas SPC 2019)	Refer to product insert and to PPG-CUH-CUH-209 on QPULSE. Administer slowly at a rate which the patient finds comfortable and which does NOT exceed 5 mL/min.


	Red Cell Concentrate (RCC)	Platelets	Solvent Detergent (SD) Plasma	Fibrinogen (RiaSTAP® 1g)
Administration Equipment	Adults: Standard blood administration set with an integral 170 – 200 µm filter. Administered using an approved CE marked infusion pump or gravity. Neonates, infants & children: Paediatric/Neonatal blood administration set with a 170 – 200 µm filter.	Platelet or standard adult / paediatric / neonatal blood administration set with an integral 170 – 200 µm filter. Platelets should NOT be administered through an administration set previously used to transfuse red cells.	Standard blood administration set with an integral 170 – 200 µm filter. Red blood cells and plasma may be given through the same administration set (BSH 2017).	IV injection <u>or</u> infusion using a syringe pump and a standard infusion set.
Commence within:	30 minutes of removal from blood fridge/igloo.	Immediately on receipt for maximum efficacy.	Immediately on receipt for maximum efficacy.	As soon as possible on receipt.
Complete transfusion within:	Must be completed within 4 hours of 'spiking' the pack and/or 4 ½ hours of removal from the blood fridge/igloo, whichever is sooner.	Must be completed <4 hours of 'spiking' the pack and within 8 hours of removal from agitator in laboratory, whichever is sooner. (NHO communication & BSH, 2017)	Must be completed within 4 hours of 'spiking' the pack and/or 8 hours of removal from the blood fridge/igloo, whichever is sooner.	Once reconstituted, administer immediately. If a delay occurs, keep at room temperature (≤25°C) & discard after 8 hours.
Miscellaneous:	Blood warmers should ONLY be used if a patient has a clinically significant cold antibody; during rapid transfusion; during elective/emergency surgery or for neonates/infants undergoing a constant rate exchange transfusion (JPAC 2014 & BSH, 2016) Blood components should be added to the blood component, as this may result in haemolysis, clotting or in compatibility. Blood components can be transfused through one lumen of a multi-lumen catheter while the other lumina are in use. Refer to PPG-CUH-CUH-13 for further guidance on use of single/multi-lumen catheters. Blood administration sets must be changed: ➢ If transfusing platelets ➢ On completion of transfusion (or at least every 12 hours if the transfusion episode is on-going.) (BSH, 2017). ➢ If infusing another fluid or medication after the current transfusion.	Platelets may NOT be available onsite, so allow time for ordering & transport from the IBTS. HLA or HPA matched platelets require special order from the National Blood Centre in Dublin.	SD Plasma must be ABO compatible (RhD type is irrelevant). Allow at least 30 minutes for thawing and issuing. Due to the large volumes required to produce haemostatic benefit, patients must have careful haemodynamic monitoring to prevent TACO (JPAC, 2014)	Do NOT store reconstituted RiaSTAP® in a fridge.

General Information:

- RCC, platelets and plasma can be administered through peripheral IV cannulae and most central venous access devices (according to manufacturer's instructions), as well as intrasosseously.
- The cannula size used to administer blood components depends on vein size and the rate of infusion required. There is no maximum or minimum size requirement.
- Prime and fully wet the filter of the blood administration giving set with the blood component.
- Priming or flushing the blood administration set with 0.9% saline is **NOT** recommended. (BSH, 2017).
- No other infusion solutions or drugs should be added to the blood component, as this may result in haemolysis, clotting or in compatibility.
- Blood components can be transfused through one lumen of a multi-lumen catheter while the other lumina are in use. Refer to PPG-CUH-CUH-13 for further guidance on use of single/multi-lumen catheters.
- Blood administration sets must be changed:
 - If transfusing platelets
 - On completion of transfusion (or at least every 12 hours if the transfusion episode is on-going.) (BSH, 2017).
 - If infusing another fluid or medication after the current transfusion.

Refer to PPG-CUH-CUH-13 on QPULSE and/or to the product inserts for further information.

Blood Component Administration Process / Checklist



***Transfusion Reaction Signs and/or Symptoms**
 Fever (Increase of 2.0 °C or more or a temperature of 39.0 °C WITHOUT any other symptoms OR if combined with other symptoms, an increase of >1.0 °C that increases temperature to >38.0 °C) / Chills / Shivering / Tachycardia / Hypo- or hypertension/ Collapse / Rigors / Flushing / Urticaria / Nausea / Vomiting / Chest or Abdominal Pain / Pain at the cannula site / Pallor/Rash/ Oedema / Low Back Pain / Bone or Muscle Pain / Shortness of Breath / Agitation or generally feeling unwell / Feeling of Doom / Respiratory Distress / Anaphylaxis / Haematuria / Diminished Urinary Output

In the event of a suspected transfusion reaction, refer to page 14 of this document for guidance.

Refer to PPG-CUH-CUH-13 on QPULSE for detailed information on the administration of blood components.

(PDA = Personal Digital Assistant, which is a handheld scanner that forms part of the Electronic Blood Tracking System [EBTS].)

Patient's Name: _____
 MRN: _____ Date Transfused: ___ / ___ / ___
Affix Unit 'Peel-Away' Label (Or manually complete)
 Unit Blood Group: _____ Component Type: _____ Unit No / Batch No: _____

Begin Transfusion Checked & Administered by: Signature 1: _____ <i>Handwrite</i> Badge/IMC No.: _____ <i>or</i> Begin Date: <u>Attach EBTS Label</u> Begin Time: _____ Ward: _____	Checked by: (If non-verbal /manual check) Signature 2: _____ Badge/IMC No.: _____
End Transfusion Signature: _____ <i>Handwrite</i> Badge/IMC No.: _____ <i>or</i> End Time: <u>Attach EBTS Label</u> Volume Transfused: _____ mL	Comments: _____ _____ _____

Observations													
Time (24 Hr. Clock)	Temp °C											Final	
40.5													
40.0	B	1											
39.5	A	5											
39.0	T	S	M							F			
38.5	E	I	N							I			
38.0	S	E	L							N			
37.5	L	I	N							A			
37.0	I	N	U							L			
36.5	N	E	T										
36.0	E	S											
35.5													
<hr/>													
210													
200													
190	O	O									O		
180	B	B									B		
170	S	S									S		
160	E	E									E		
150	R	R									R		
140	V	V									V		
130	A	A									A		
120	T	T									T		
110	I	I									I		
100	O	O									O		
90	N	N									N		
80	S	S									S		
70													
60													
50													
Pulse													
Resps													
SpO ₂													
IV Site Satisfactory													
Initials													

Patient's Name: _____
 MRN: _____ Date Transfused: ___ / ___ / ___
Affix Unit 'Peel-Away' Label (Or manually complete)
 Unit Blood Group: _____ Component Type: _____ Unit No / Batch No: _____

Begin Transfusion Checked & Administered by: Signature 1: _____ <i>Handwrite</i> Badge/IMC No.: _____ <i>or</i> Begin Date: <u>Attach EBTS Label</u> Begin Time: _____ Ward: _____	Checked by: (If non-verbal /manual check) Signature 2: _____ Badge/IMC No.: _____
End Transfusion Signature: _____ <i>Handwrite</i> Badge/IMC No.: _____ <i>or</i> End Time: <u>Attach EBTS Label</u> Volume Transfused: _____ mL	Comments: _____ _____ _____

Observations													
Time (24 Hr. Clock)	Temp °C											Final	
40.5													
40.0	B	1											
39.5	A	5											
39.0	T	S	M							F			
38.5	E	I	N							I			
38.0	S	E	L							N			
37.5	L	I	N							A			
37.0	I	N	U							L			
36.5	N	E	T										
36.0	E	S											
35.5													
<hr/>													
210													
200													
190	O	O									O		
180	B	B									B		
170	S	S									S		
160	E	E									E		
150	R	R									R		
140	V	V									V		
130	A	A									A		
120	T	T									T		
110	I	I									I		
100	O	O									O		
90	N	N									N		
80	S	S									S		
70													
60													
50													
Pulse													
Resps													
SpO ₂													
IV Site Satisfactory													
Initials													

Patient's Name: _____

MRN: _____ Date Transfused: ___ / ___ / ___

Affix Unit 'Peel-Away' Label (Or manually complete)

Unit Blood Group:	Component Type:	Unit No / Batch No:
_____	_____	_____

Patient's Name: _____

MRN: _____ Date Transfused: ___ / ___ / ___

Affix Unit 'Peel-Away' Label (Or manually complete)

Unit Blood Group:	Component Type:	Unit No / Batch No:
_____	_____	_____

Patient's Name: _____

MRN: _____ Date Transfused: ___ / ___ / ___

Affix Unit 'Peel-Away' Label (Or manually complete)

Unit Blood Group:	Component Type:	Unit No / Batch No:
_____	_____	_____

Patient's Name: _____

MRN: _____ Date Transfused: ___ / ___ / ___

Affix Unit 'Peel-Away' Label (Or manually complete)

Unit Blood Group:	Component Type:	Unit No / Batch No:
_____	_____	_____

Begin Transfusion		Checked by: <i>(If non-verbal /manual check)</i>	
Checked & Administered by:		Signature 1: _____	
Signature 1: _____ <i>Handwrite</i>		Signature 2: _____	
Badge/IMC No.: _____ <i>or</i>		_____	
Begin Date: _____ <i>Attach EBTS Label</i>		_____	
Begin Time: _____		Badge/IMC No.: _____	
Ward: _____		_____	
End Transfusion		Comments:	
Signature: _____ <i>Handwrite</i>		_____	
Badge/IMC No.: _____ <i>or</i>		_____	
End Time: _____ <i>Attach EBTS Label</i>		_____	
Volume Transfused: _____ mL		_____	

Begin Transfusion		Checked by: <i>(If non-verbal /manual check)</i>	
Checked & Administered by:		Signature 1: _____	
Signature 1: _____ <i>Handwrite</i>		Signature 2: _____	
Badge/IMC No.: _____ <i>or</i>		_____	
Begin Date: _____ <i>Attach EBTS Label</i>		_____	
Begin Time: _____		Badge/IMC No.: _____	
Ward: _____		_____	
End Transfusion		Comments:	
Signature: _____ <i>Handwrite</i>		_____	
Badge/IMC No.: _____ <i>or</i>		_____	
End Time: _____ <i>Attach EBTS Label</i>		_____	
Volume Transfused: _____ mL		_____	

Begin Transfusion		Checked by: <i>(If non-verbal /manual check)</i>	
Checked & Administered by:		Signature 1: _____	
Signature 1: _____ <i>Handwrite</i>		Signature 2: _____	
Badge/IMC No.: _____ <i>or</i>		_____	
Begin Date: _____ <i>Attach EBTS Label</i>		_____	
Begin Time: _____		Badge/IMC No.: _____	
Ward: _____		_____	
End Transfusion		Comments:	
Signature: _____ <i>Handwrite</i>		_____	
Badge/IMC No.: _____ <i>or</i>		_____	
End Time: _____ <i>Attach EBTS Label</i>		_____	
Volume Transfused: _____ mL		_____	

Begin Transfusion		Checked by: <i>(If non-verbal /manual check)</i>	
Checked & Administered by:		Signature 1: _____	
Signature 1: _____ <i>Handwrite</i>		Signature 2: _____	
Badge/IMC No.: _____ <i>or</i>		_____	
Begin Date: _____ <i>Attach EBTS Label</i>		_____	
Begin Time: _____		Badge/IMC No.: _____	
Ward: _____		_____	
End Transfusion		Comments:	
Signature: _____ <i>Handwrite</i>		_____	
Badge/IMC No.: _____ <i>or</i>		_____	
End Time: _____ <i>Attach EBTS Label</i>		_____	
Volume Transfused: _____ mL		_____	

Observations

Time (24 Hr. Clock)										
40.5										
40.0										
39.5	B	5								
39.0	A									F
38.5	S	M								I
38.0	E	I								N
37.5	L	N								A
37.0	I	N								L
36.5	N									
36.0	E	S								
35.5										
210										
200										
190										
180	O	O								O
170	B	B								B
160	S	S								S
150	E	E								E
140	R	R								R
130	V	V								V
120	A	A								A
110	T	T								T
100	I	I								I
90	O	O								O
80	N	N								N
70	S	S								S
60										
50										
Pulse										
Resps										
SpO₂										
IV Site Satisfactory										
Initials										

Observations

Time (24 Hr. Clock)										
40.5										
40.0										
39.5	B	5								
39.0	A									F
38.5	S	M								I
38.0	E	I								N
37.5	L	N								A
37.0	I	N								L
36.5	N									
36.0	E	S								
35.5										
210										
200										
190										
180	O	O								O
170	B	B								B
160	S	S								S
150	E	E								E
140	R	R								R
130	V	V								V
120	A	A								A
110	T	T								T
100	I	I								I
90	O	O								O
80	N	N								N
70	S	S								S
60										
50										
Pulse										
Resps										
SpO₂										
IV Site Satisfactory										
Initials										

Observations

Time (24 Hr. Clock)										
40.5										
40.0										
39.5	B	5								
39.0	A									F
38.5	S	M								I
38.0	E	I								N
37.5	L	N								A
37.0	I	N								L
36.5	N									
36.0	E	S								
35.5										
210										
200										
190										
180	O	O								O
170	B	B								B
160	S	S								S
150	E	E								E
140	R	R								R
130	V	V								V
120	A	A								A
110	T	T								T
100	I	I								I
90	O	O								O
80	N	N								N
70	S	S								S
60										
50										
Pulse										
Resps										
SpO₂										
IV Site Satisfactory										
Initials										

Observations

Time (24 Hr. Clock)										
40.5										
40.0										
39.5	B	5								
39.0	A									F
38.5	S	M								I
38.0	E	I								N
37.5	L	N								A
37.0	I	N								L
36.5	N									
36.0	E	S								
35.5										
210										
200										
190										
180	O	O								O
170	B	B								B
160	S	S								S
150	E	E								E
140	R	R								R
130	V	V								V
120	A	A								A
110	T	T								T
100	I	I								I
90	O	O								O
80	N	N								N
70	S	S								S
60										
50										
Pulse										
Resps										
SpO₂										
IV Site Satisfactory										
Initials										

Patient's Name: _____
 MRN: _____ Date Transfused: ___ / ___ / ___
Affix Unit 'Peel-Away' Label (Or manually complete)
 Unit Blood Group: _____ Component Type: _____ Unit No / Batch No: _____

Begin Transfusion		Checked & Administered by:		Checked by: <i>(If non-verbal /manual check)</i>	
Signature 1: _____ <i>Handwrite</i>		Signature 1: _____ <i>Handwrite</i>		Signature 2: _____ <i>(If non-verbal /manual check)</i>	
Badge/IMC No.: _____ <i>or</i>		Badge/IMC No.: _____ <i>or</i>		Signature 2: _____	
Begin Date: _____ <i>Attach EBTS Label</i>		Begin Date: _____ <i>Attach EBTS Label</i>		Signature 2: _____	
Begin Time: _____		Begin Time: _____		Badge/IMC No.: _____	
Ward: _____		Ward: _____		Badge/IMC No.: _____	
End Transfusion			Comments:		
Signature: _____ <i>Handwrite</i>					
Badge/IMC No.: _____ <i>or</i>					
End Time: _____ <i>Attach EBTS Label</i>					
Volume Transfused: _____ mL					

Observations

Time (24 Hr. Clock)									
40.5									
40.0	B	5							
39.5	A								F
39.0	S	M							I
38.5	S								N
38.0	E	I							A
37.5	L	N							L
37.0	I	U							
36.5	N	T							
36.0	E	S							
35.5									
210									
200									
190	O	O							O
180	B	B							B
170	S	S							S
160	E	E							E
150	R	R							R
140	V	V							V
130	A	A							A
120	T	T							T
110	I	I							I
100	O	O							O
90	N	N							N
80	S	S							S
70									
60									
50									
Pulse									
Resps									
SpO ₂									
IV Site Satisfactory									
Initials									

Patient's Name: _____
 MRN: _____ Date Transfused: ___ / ___ / ___
Affix Unit 'Peel-Away' Label (Or manually complete)
 Unit Blood Group: _____ Component Type: _____ Unit No / Batch No: _____


Begin Transfusion		Checked & Administered by:		Checked by: <i>(If non-verbal /manual check)</i>	
Signature 1: _____ <i>Handwrite</i>		Signature 1: _____ <i>Handwrite</i>		Signature 2: _____ <i>(If non-verbal /manual check)</i>	
Badge/IMC No.: _____ <i>or</i>		Badge/IMC No.: _____ <i>or</i>		Signature 2: _____	
Begin Date: _____ <i>Attach EBTS Label</i>		Begin Date: _____ <i>Attach EBTS Label</i>		Signature 2: _____	
Begin Time: _____		Begin Time: _____		Badge/IMC No.: _____	
Ward: _____		Ward: _____		Badge/IMC No.: _____	
End Transfusion			Comments:		
Signature: _____ <i>Handwrite</i>					
Badge/IMC No.: _____ <i>or</i>					
End Time: _____ <i>Attach EBTS Label</i>					
Volume Transfused: _____ mL					

Observations

Time (24 Hr. Clock)									
40.5									
40.0	B	5							
39.5	A								F
39.0	S	M							I
38.5	S								N
38.0	E	I							A
37.5	L	N							L
37.0	I	U							
36.5	N	T							
36.0	E	S							
35.5									
210									
200									
190	O	O							O
180	B	B							B
170	S	S							S
160	E	E							E
150	R	R							R
140	V	V							V
130	A	A							A
120	T	T							T
110	I	I							I
100	O	O							O
90	N	N							N
80	S	S							S
70									
60									
50									
Pulse									
Resps									
SpO ₂									
IV Site Satisfactory									
Initials									


Guidance on use of Irradiated or CMV negative Blood Components

1. Irradiated Requirements Algorithm ¹




* The lifetime requirement for ALL allogeneic BMT/HSCT patients is a local practice, which may differ in other hospitals.
 ^ In emergencies, if irradiated components are not available, non-irradiated components may be transfused to avoid delays.

2. CMV Negative Requirements Algorithm ²



(NOTE: Clinical staff should ensure that ALL potential BMT/HSCT patients are CMV screened BEFORE transfusion.)
 This includes patients who are awaiting/have had a BM/HSC transplant (irrespective of the CMV serology status of the donor/recipient); AIDS / HIV or immunodeficient patients; infants > 6 months old and those who are awaiting / have had solid organ transplants, as standard leucodepleted red cells and platelets provide sufficient protection.
 References:
 1. British Society for Haematology (BSH) guidelines on the use of Irradiated blood components, August 2020.
 2. National Transfusion Advisory Group (NTAG) guidelines for use of CMV antibody screened negative (CMV negative) cellular blood components (red cells, platelets and granulocytes) in the Irish healthcare setting, September 2020.

Paediatric Major Transfusion Protocol (MTP)



- Optimise:**
- Oxygenation
 - Cardiac Output
 - Tissue Perfusion
 - Metabolic State
 - Watch ECG, O₂ saturation and BP
- Monitor (every 30 – 60 minutes):**
- FBC
 - PT / APTT / Fibrinogen
 - Calcium and Magnesium
 - VBG
- If bleeding continues, aim for:**
- Hb: > 8.0g/dL
 - Platelets:
 - 50-100 x 10⁹/L
 - 100 if ICH / Life threatening bleeding
 - PT/APTT: < 1.5 x normal
 - Fibrinogen: > 1.5g/L
 - Temperature: >35°C
 - pH: > 7.2
 - Base excess: < 6
 - Lactate: < 1mmol/L
 - Ca⁺⁺: >1.1mmol/L

Major Haemorrhage/Emergency/Batch Product Transfusion Record

Patient's Name: _____ DOB: _____ MRN: _____


This section may be used to record transfusion during **Major Haemorrhage**, in **Intensive Care**, **High Dependency**, **Theatre** or to record the administration of **Batch Products** (e.g. albumin, coagulation factor concentrates, immunoglobulins etc.).

- All procedures, including **pre-administration checks**, must be adhered to irrespective of the clinical urgency.
- Observations must be recorded** at the recommended intervals in the anaesthetic sheet, EWS or approved IT system (e.g. ICIP).
- After the emergency, reconcile all blood components/products to ensure that **ALL unit/batch numbers have been recorded**.

Blood Component/Product Details	Begin Tx	End Tx
1. Unit/Batch No.: <i>Affix Pink Traceability Sticker</i>	Signature 1: _____ ID Badge/IMC No.: <i>EBTS</i> Begin Date: _____ Begin Time: _____ <i>'Begin' Label</i>	Signature: _____ ID Badge/IMC No.: <i>EBTS</i> End Time: _____ Volume Transfused: _____ mL <i>'End' Label</i>
2nd Checker: (if non-verbal patient / manual 2 person checks performed) Signature 2: _____ ID Badge/IMC No.: _____		
2. Unit/Batch No.: <i>Affix Pink Traceability Sticker</i>	Signature 1: _____ ID Badge/IMC No.: <i>EBTS</i> Begin Date: _____ Begin Time: _____ <i>'Begin' Label</i>	Signature: _____ ID Badge/IMC No.: <i>EBTS</i> End Time: _____ Volume Transfused: _____ mL <i>'End' Label</i>
2nd Checker: (if non-verbal patient / manual 2 person checks performed) Signature 2: _____ ID Badge/IMC No.: _____		
3. Unit/Batch No.: <i>Affix Pink Traceability Sticker</i>	Signature 1: _____ ID Badge/IMC No.: <i>EBTS</i> Begin Date: _____ Begin Time: _____ <i>'Begin' Label</i>	Signature: _____ ID Badge/IMC No.: <i>EBTS</i> End Time: _____ Volume Transfused: _____ mL <i>'End' Label</i>
2nd Checker: (if non-verbal patient / manual 2 person checks performed) Signature 2: _____ ID Badge/IMC No.: _____		
4. Unit/Batch No.: <i>Affix Pink Traceability Sticker</i>	Signature 1: _____ ID Badge/IMC No.: <i>EBTS</i> Begin Date: _____ Begin Time: _____ <i>'Begin' Label</i>	Signature: _____ ID Badge/IMC No.: <i>EBTS</i> End Time: _____ Volume Transfused: _____ mL <i>'End' Label</i>
2nd Checker: (if non-verbal patient / manual 2 person checks performed) Signature 2: _____ ID Badge/IMC No.: _____		
5. Unit/Batch No.: <i>Affix Pink Traceability Sticker</i>	Signature 1: _____ ID Badge/IMC No.: <i>EBTS</i> Begin Date: _____ Begin Time: _____ <i>'Begin' Label</i>	Signature: _____ ID Badge/IMC No.: <i>EBTS</i> End Time: _____ Volume Transfused: _____ mL <i>'End' Label</i>
2nd Checker: (if non-verbal patient / manual 2 person checks performed) Signature 2: _____ ID Badge/IMC No.: _____		
6. Unit/Batch No.: <i>Affix Pink Traceability Sticker</i>	Signature 1: _____ ID Badge/IMC No.: <i>EBTS</i> Begin Date: _____ Begin Time: _____ <i>'Begin' Label</i>	Signature: _____ ID Badge/IMC No.: <i>EBTS</i> End Time: _____ Volume Transfused: _____ mL <i>'End' Label</i>
2nd Checker: (if non-verbal patient / manual 2 person checks performed) Signature 2: _____ ID Badge/IMC No.: _____		

For detailed information, refer to PPG-CUH-CUH-210 on QPULSE. Advisory services are also available from the haematology team.

Transfusion Reaction Management & Investigation Algorithm



For detailed information, refer to PPG-CUH-CUH-30 on QPULSE. Advisory services are also available from the haematology team.

Suspected Transfusion Reaction Report

All suspected transfusion reactions, including delayed reactions, must be reported to the CUH Blood Transfusion lab.

This form must be completed by the nurse/midwife and/or doctor who observed/managed the reaction

Name: _____
MRN: _____
Consultant: _____
Ward: _____

Product/Component: _____

Unit No.(s): _____

Volume transfused: _____

Date & Time of reaction: _____

Clinical Diagnosis: _____

Reason for Transfusion: _____

Prophylactic medication administered? Yes No

If yes, please specify: _____

Previous reactions? Yes No Unknown

If yes, give details: _____

Clinical Signs & Symptoms of a Transfusion Reaction: (Please circle any NEW or WORSENING signs/symptoms)

Pre-transfusion obs: Temp. _____ Pulse _____ BP _____ RR _____ SpO₂ _____

Reaction obs: Temp. _____ Pulse _____ BP _____ RR _____ SpO₂ _____

Pyrexia: Specify increase from baseline: _____ °C	Max. Temp.: _____ °C	Dyspnoea
Chills / Shivers	Back pain	Orthopnoea
Rigors	Loin pain	Cyanosis
Facial flushing	Bone pain	Hypertension
Headache	Muscle pain	Increased JVP
General malaise	Tachycardia	Peripheral oedema
Diffuse bleeding (acute onset)	Agitation / Anxiety	Pulmonary oedema
Haematuria/Dark urine	Falling Hb	Positive fluid balance
Decreased urinary output	Jaundice	Crepes on chest auscultation
Pain along infusion site	Pallor	Lung infiltrates on chest X-ray
	Collapse	
	Hypotension	
	Diarrhoea	
	Nausea/vomiting	
	Anaphylaxis	
	Angioedema	
	Throat tightness	
	Wheezing	
	Cough	
	Urticaria/Hives	
	Rash	
	Pruritus/Itch	
	Facial/Lip tingling	
	Dysphonia/Hoarseness	
	Sub-sternal discomfort	
	Bradycardia	
	Tachypnoea	
	Falling SpO ₂	

Other symptoms (please specify): _____

Urinalysis Dipstick Results: (To be tested on ward)

1st urine voided after reaction: Urobilinogen: _____ Haemoglobinuria (Free Hb): _____ WBCs: _____

Management of the Suspected Transfusion Reaction: (Refer to algorithm on page 14 for guidance)

Does the patient identity match the ID band and the laboratory compatibility tag on the unit? * Yes No*

Is the unit ABO and RhD type compatible with the patient's blood group? * Yes No*

Is the appearance of the unit normal? (i.e. not leaking, discoloured, cloudy, clotted etc.) Yes No

If confirmed as a possible transfusion reaction, has the blood transfusion laboratory been notified? Yes No

Required blood tests/investigations performed, as per transfusion reaction algorithm on page 14? Yes No

(* If no, notify the blood transfusion laboratory **immediately**, as other patients may be at risk)

Give a detailed description of events, including management/treatment: (To be completed by doctor)

Doctor's Signature: _____ IMC No.: _____ Bleep No.: _____

Nurse's/Midwife's Signature: _____ ID Badge No.: _____